Pacira BioSciences (NASDAQ:PCRX) Hits New 52-Week Low at $25.74

Pacira BioSciences, Inc. (NASDAQ:PCRX)’s share price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $25.74 and last traded at $25.76, with a volume of 63285 shares traded. The stock had previously closed at $26.25.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Pacira BioSciences in a research report on Thursday, February 8th. Royal Bank of Canada decreased their price objective on shares of Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price objective on shares of Pacira BioSciences in a research report on Monday, March 4th. JPMorgan Chase & Co. started coverage on shares of Pacira BioSciences in a research report on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price target for the company. Finally, TheStreet raised shares of Pacira BioSciences from a “d+” rating to a “c” rating in a research report on Thursday, February 29th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $49.50.

Pacira BioSciences Stock Up 2.7 %

The company has a quick ratio of 4.17, a current ratio of 5.24 and a debt-to-equity ratio of 0.59. The company has a market cap of $1.25 billion, a PE ratio of 33.10 and a beta of 0.76. The firm’s fifty day simple moving average is $28.91 and its 200-day simple moving average is $29.73.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.71 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.71. The business had revenue of $181.24 million for the quarter, compared to the consensus estimate of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. As a group, equities research analysts expect that Pacira BioSciences, Inc. will post 2.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Gary W. Pace sold 1,066 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the transaction, the director now owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the completion of the sale, the director now owns 22,127 shares of the company’s stock, valued at $677,086.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary W. Pace sold 1,066 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the sale, the director now directly owns 140,384 shares of the company’s stock, valued at approximately $4,165,193.28. The disclosure for this sale can be found here. 6.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pacira BioSciences

Large investors have recently made changes to their positions in the business. Rice Hall James & Associates LLC grew its holdings in Pacira BioSciences by 0.7% during the 1st quarter. Rice Hall James & Associates LLC now owns 1,043,540 shares of the company’s stock valued at $30,492,000 after purchasing an additional 7,571 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Pacira BioSciences by 114.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 10,188 shares of the company’s stock valued at $298,000 after purchasing an additional 5,433 shares in the last quarter. Tributary Capital Management LLC grew its holdings in Pacira BioSciences by 3.7% during the 1st quarter. Tributary Capital Management LLC now owns 250,868 shares of the company’s stock valued at $7,330,000 after purchasing an additional 8,863 shares in the last quarter. Bridge City Capital LLC acquired a new stake in Pacira BioSciences during the 1st quarter valued at $1,810,000. Finally, Congress Asset Management Co. MA grew its holdings in Pacira BioSciences by 1.2% during the 1st quarter. Congress Asset Management Co. MA now owns 88,962 shares of the company’s stock valued at $2,599,000 after purchasing an additional 1,095 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.